Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Shareholder Meeting (November 2022)
9 slides from Argenica Therapeutics's shareholder meeting presentation, Nov 24, 2022
Slide 1: Annual General Meeting Presentation
ANNUAL GENERAL MEETING ARGENICA THERAPEUTICS PRESENTATION ASX: AGN 24 NOVEMBER 2022 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Key Company Metrics
KEY COMPANY METRICS $8.2M RECENT R&D REBATE PHASE 1 TRIAL CASH @ BANK1 $1.38M FUNDED ARGENICA THERAPEUTICS 86.9M $48M STRONG SHARES ON ISSUE MARKET CAP2 SHARE PRICE PERFORMANCE SINCE IPO (1) Cash balance as @ 30 September 2022 3 (2) Calculated with closing price on @ 22nd November being $0.555 www.a
Slide 4: Clinical Trial Roadmap for Stroke
CLINICAL TRIAL ROADMAP FOR STROKE Oct Nov Dec Jan Feb March April May June ARGENICA HAS ACHIEVED First patient ALL STRATEGIC PRIORITIES successfully dosed SET OUT AT OUR IPO First cohort completed Secured local and international Second cohort completed ARGENICA THERAPEUTICS manufacturing capabilitie
Slide 5: Phase 1 Trial Update
PHASE 1 TRIAL UPDATE 1. FOLLOWING DOSING OF THE FIRST 2 COHORTS NO CLINICALLY SIGNIFICANT ADVERSE EVENTS HAVE BEEN REPORTED 2. ARGENICA THERAPEUTICS THIRD COHORT SENTINEL GROUP SHOWED NO SAFETY ISSUES 3. POSITIVE DATA GENERATED TO DATE ALLOWING COMPANY TO PLAN FOR PHASE 2 4. FOURTH COHORT DOSING HAS
Slide 6: ARG-007 Is a Versatile Technology Platform
DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 STROKE Damage to the brain from interruption of its blood supply ARG-007 SIS IS A VERSATILE Surgically Induced Stroke (SIS) occurs during or after surgery TECHNOLOGY HIE PLATFORM ARGENICA THERAPEUTICS Hypoxic ischemic encephalopathy (HIE) develops durin
Slide 7: Advancing Clinical Studies
ADVANCING CLINICAL STUDIES PHASE 1 SAFETY & DOSAGE DATA CAN POTENTIALLY BE USED TO MOVE DIRECTLY INTO MULTIPLE PHASE 2 STUDIES STROKE HIE TRAUMATIC BRAIN INJURY Preclinical studies have shown Argenica’s Preclinical studies show that ARG-007 Data collected from the Phase 1 ARG-007 provides neuroprote
Slide 8: Investment Highlights
INVESTMENT HIGHLIGHTS 25+ PUBLISHED STRONG PHASE 1 PAPERS BALANCE SHEET FULLY FUNDED ARGENICA THERAPEUTICS MULTIPLE POSITIVE EXCEPTIONAL APPLICATIONS PHASE 1 TRIAL & EXPERIENCED & PIPELINE PROGRESS TEAM + BOARD 8 www.argenica.com.au
Slide 9: For further information please contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 9 www.argenica.com.au
Argenica Therapeutics — Shareholder Meeting (November 2022) on 6ix